澳门六合彩高手

Pour les actualités en fran?ais, voir la page News in French.

Agence Iter France welcomes new Director

On Tuesday, it was time to say goodbye to Francois Gauché (left) and to welcome Jér?me Paméla (centre). Photo: Agence Iter France.

Starting 1 January 2010, Jér?me Paméla, the former leader of the European Fusion Development Agreement (EFDA), will take on a new role as Director of Agence Iter France. Paméla succeeds Francois Gauché, who is moving on will take over a new responsibility leading the French Generation IV (Gen IV) reactor program.

Jér?me Paméla was born in France, in 1955. He graduated from the "Ecole Polytechnique" in Paris in 1977, and in 1978 he obtained a diploma in nuclear and particle physics at Orsay University. In 1984, Jér?me Paméla finished his PhD on CELLO, a high energy physics experiment run on the Petra e+/e- Collider located at the DESY Laboratory in Hamburg. Between 1983 and 1984, Dr. Paméla was also involved in the DELPHI Project at the LEP/CERN, Geneva. After his PhD, he changed his field of research from high energy physics to thermonuclear fusion.

In 1984 Paméla joined the French Atomic Energy Agency (CEA) Controlled Thermonuclear Fusion Department in Fontenay-aux-Roses near Paris, and then moved to Cadarache in southern France in 1986. Jér?me Paméla was involved in the development of negative ion-based neutral beam heating, first as a physicist, and then as Group and European Task Area Leader. During several years he was responsible for collaboration with Japan in that field. In 1995-1996, he was involved in and ultimately led a first phase of studies preparing Cadarache to bid for siting 澳门六合彩高手.

In 1996, Jér?me Paméla was appointed head of the Controlled Thermonuclear Fusion Department of the CEA and Head of the Euratom-CEA Association. In September 1999 he was seconded to Culham, UK, as EFDA Associate Leader, in charge of the Joint European Torus (JET).

Paméla is married and has four children.

An interview with Jér?me Paméla looking back on his time with EFDA and reflecting on his new assignment was published in the December 2009 issue of the EFDA Newsletter.